Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients
American Society of Haematology Meeting, New Orleans, 5-9th December 2009. ecancer Managing Editor Gordon McVie gives his roundup of ASH 2009 news, excluding Multiple Myeloma, which can be found in a separate video.
Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Choosing the right Tyrosine Kinase Inhibitors (TKI) for CML Patients
Multiple Myeloma: evolving paradigm - Panel Discussion
Advancements in paediatric Acute lymphoblastic leukemia management
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
Choosing 1st line TKI Wisely in patients with CML
Choosing Wisely in endometrial & cervix cancers: Medical therapy
Immunotherapy resistance pathways investigated to tailor combination NSCLC therapy